FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098194481> ?p ?o ?g. }

• W2098194481 endingPage "1243" @default.
• W2098194481 startingPage "1231" @default.
• W2098194481 abstract "Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35–70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. Findings We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5·0 years previously [IQR 2·0–10·0]) and 2292 had stroke (4·0 years previously [2·0–8·0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25·3%), β blockers (17·4%), ACE inhibitors or ARBs (19·5%), or statins (14·6%). Use was highest in high-income countries (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 49·8%, and statins 66·5%), lowest in low-income countries (8·8%, 9·7%, 5·2%, and 3·3%, respectively), and decreased in line with reduction of country economic status (ptrend<0·0001 for every drug type). Fewest patients received no drugs in high-income countries (11·2%), compared with 45·1% in upper middle-income countries, 69·3% in lower middle-income countries, and 80·2% in low-income countries. Drug use was higher in urban than rural areas (antiplatelet drugs 28·7% urban vs 21·3% rural, β blockers 23·5% vs 15·6%, ACE inhibitors or ARBs 22·8% vs 15·5%, and statins 19·9% vs 11·6%; all p<0·0001), with greatest variation in poorest countries (pinteraction<0·0001 for urban vs rural differences by country economic status). Country-level factors (eg, economic status) affected rates of drug use more than did individual-level factors (eg, age, sex, education, smoking status, body-mass index, and hypertension and diabetes statuses). Interpretation Because use of secondary prevention medications is low worldwide—especially in low-income countries and rural areas—systematic approaches are needed to improve the long-term use of basic, inexpensive, and effective drugs. Funding Full funding sources listed at end of paper (see Acknowledgments). Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35–70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5·0 years previously [IQR 2·0–10·0]) and 2292 had stroke (4·0 years previously [2·0–8·0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25·3%), β blockers (17·4%), ACE inhibitors or ARBs (19·5%), or statins (14·6%). Use was highest in high-income countries (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 49·8%, and statins 66·5%), lowest in low-income countries (8·8%, 9·7%, 5·2%, and 3·3%, respectively), and decreased in line with reduction of country economic status (ptrend<0·0001 for every drug type). Fewest patients received no drugs in high-income countries (11·2%), compared with 45·1% in upper middle-income countries, 69·3% in lower middle-income countries, and 80·2% in low-income countries. Drug use was higher in urban than rural areas (antiplatelet drugs 28·7% urban vs 21·3% rural, β blockers 23·5% vs 15·6%, ACE inhibitors or ARBs 22·8% vs 15·5%, and statins 19·9% vs 11·6%; all p<0·0001), with greatest variation in poorest countries (pinteraction<0·0001 for urban vs rural differences by country economic status). Country-level factors (eg, economic status) affected rates of drug use more than did individual-level factors (eg, age, sex, education, smoking status, body-mass index, and hypertension and diabetes statuses). Because use of secondary prevention medications is low worldwide—especially in low-income countries and rural areas—systematic approaches are needed to improve the long-term use of basic, inexpensive, and effective drugs." @default.
• W2098194481 created "2016-06-24" @default.
• W2098194481 creator A5005906845 @default.
• W2098194481 creator A5011268662 @default.
• W2098194481 creator A5012111658 @default.
• W2098194481 creator A5013408607 @default.
• W2098194481 creator A5016340724 @default.
• W2098194481 creator A5018419311 @default.
• W2098194481 creator A5021591848 @default.
• W2098194481 creator A5023361030 @default.
• W2098194481 creator A5026568725 @default.
• W2098194481 creator A5031520477 @default.
• W2098194481 creator A5039145780 @default.
• W2098194481 creator A5045264049 @default.
• W2098194481 creator A5045783683 @default.
• W2098194481 creator A5050936489 @default.
• W2098194481 creator A5051270709 @default.
• W2098194481 creator A5054103199 @default.
• W2098194481 creator A5055200248 @default.
• W2098194481 creator A5065568572 @default.
• W2098194481 creator A5068719503 @default.
• W2098194481 creator A5069728608 @default.
• W2098194481 creator A5077219405 @default.
• W2098194481 creator A5081443868 @default.
• W2098194481 creator A5086287744 @default.
• W2098194481 date "2011-10-01" @default.
• W2098194481 modified "2023-10-18" @default.
• W2098194481 title "Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey" @default.
• W2098194481 cites W180946569 @default.
• W2098194481 cites W1966953116 @default.
• W2098194481 cites W1975202701 @default.
• W2098194481 cites W1989109964 @default.
• W2098194481 cites W1992806887 @default.
• W2098194481 cites W2002189205 @default.
• W2098194481 cites W2023755744 @default.
• W2098194481 cites W2025782661 @default.
• W2098194481 cites W2037499468 @default.
• W2098194481 cites W2058939989 @default.
• W2098194481 cites W2076817544 @default.
• W2098194481 cites W2079498268 @default.
• W2098194481 cites W2083377545 @default.
• W2098194481 cites W2102498368 @default.
• W2098194481 cites W2120335639 @default.
• W2098194481 cites W2124411528 @default.
• W2098194481 cites W2128509884 @default.
• W2098194481 cites W2132816662 @default.
• W2098194481 cites W2135293213 @default.
• W2098194481 cites W2136786020 @default.
• W2098194481 cites W2142264046 @default.
• W2098194481 cites W2147631211 @default.
• W2098194481 cites W2150150721 @default.
• W2098194481 cites W2153523117 @default.
• W2098194481 cites W2155121555 @default.
• W2098194481 cites W2155441883 @default.
• W2098194481 cites W2157622195 @default.
• W2098194481 cites W2163207768 @default.
• W2098194481 cites W2164089346 @default.
• W2098194481 cites W2188950424 @default.
• W2098194481 cites W4211122169 @default.
• W2098194481 cites W4239471829 @default.
• W2098194481 doi "https://doi.org/10.1016/s0140-6736(11)61215-4" @default.
• W2098194481 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21872920" @default.
• W2098194481 hasPublicationYear "2011" @default.
• W2098194481 type Work @default.
• W2098194481 sameAs 2098194481 @default.
• W2098194481 citedByCount "776" @default.
• W2098194481 countsByYear W20981944812012 @default.
• W2098194481 countsByYear W20981944812013 @default.
• W2098194481 countsByYear W20981944812014 @default.
• W2098194481 countsByYear W20981944812015 @default.
• W2098194481 countsByYear W20981944812016 @default.
• W2098194481 countsByYear W20981944812017 @default.
• W2098194481 countsByYear W20981944812018 @default.
• W2098194481 countsByYear W20981944812019 @default.
• W2098194481 countsByYear W20981944812020 @default.
• W2098194481 countsByYear W20981944812021 @default.
• W2098194481 countsByYear W20981944812022 @default.
• W2098194481 countsByYear W20981944812023 @default.
• W2098194481 crossrefType "journal-article" @default.
• W2098194481 hasAuthorship W2098194481A5005906845 @default.
• W2098194481 hasAuthorship W2098194481A5011268662 @default.
• W2098194481 hasAuthorship W2098194481A5012111658 @default.
• W2098194481 hasAuthorship W2098194481A5013408607 @default.
• W2098194481 hasAuthorship W2098194481A5016340724 @default.
• W2098194481 hasAuthorship W2098194481A5018419311 @default.
• W2098194481 hasAuthorship W2098194481A5021591848 @default.
• W2098194481 hasAuthorship W2098194481A5023361030 @default.
• W2098194481 hasAuthorship W2098194481A5026568725 @default.
• W2098194481 hasAuthorship W2098194481A5031520477 @default.
• W2098194481 hasAuthorship W2098194481A5039145780 @default.
• W2098194481 hasAuthorship W2098194481A5045264049 @default.
• W2098194481 hasAuthorship W2098194481A5045783683 @default.
• W2098194481 hasAuthorship W2098194481A5050936489 @default.
• W2098194481 hasAuthorship W2098194481A5051270709 @default.
• W2098194481 hasAuthorship W2098194481A5054103199 @default.
• W2098194481 hasAuthorship W2098194481A5055200248 @default.
• W2098194481 hasAuthorship W2098194481A5065568572 @default.
• W2098194481 hasAuthorship W2098194481A5068719503 @default.

• next